


The payers' perspective on access to innovation

Brussels, 10 May 2017





Our 5 priority areas

Steering R&D to public health needs

**Ensuring the evidence base for innovation
through strengthened HTA**

**Strengthening national P&R mechanisms in the
interests of patients, payers and society**

**Increasing transparency around innovative
pharmaceuticals**

**Supporting innovation in the context of
sustainable healthcare systems**

Steering R&D to public health needs

**WHO Priority
Medicines Report
2013: chronic
diseases, cancer...**

**Public investment
reflected in the
price**

Ensuring the evidence base for innovation through strengthened HTA

Strengthening national P&R mechanisms in the interests of patients, payers & society

Increasing transparency around innovative pharmaceuticals

Supporting innovation in the context of sustainable healthcare systems



Steering R&D to public health needs

Ensuring the evidence base for innovation through strengthened HTA

Transparent HTA tools and processes to support national P&R decisions along the lifecycle

EU-level cooperation: exchange of information, re-use of joint work (voluntary)

Cooperation regulatory-HTA: early dialogue, early access to clinical data

Strengthening national P&R mechanisms in the interests of patients, payers & society

Increasing transparency around innovative pharmaceuticals

Supporting innovation in the context of sustainable healthcare systems



Steering R&D to public health needs

Ensuring the evidence base for innovation through strengthened HTA

Strengthening national P&R mechanisms in the interests of patients, payers & society

**Reimbursement
based on
proven patient
relevant benefit
(HTA)**

**Affordable
prices to allow
access to all**

**Flexible P&R as
part of a
transparent and
well-regulated
early access
only in case of
unmet need**

**Voluntary
collaboration
between
Member States:
price
negotiations &
procurement**

Increasing transparency around innovative pharmaceuticals

Supporting innovation in the context of sustainable healthcare systems



Steering R&D to public health needs

Ensuring the evidence base for innovation through strengthened HTA

Strengthening national P&R mechanisms in the interests of patients, payers & society

Increasing transparency around innovative pharmaceuticals

Clinical trial
data

Cost of R&D

Pharmaceutical
prices &
expenditures
(Council
Conclusions
June 2016)

Supporting innovation in the context of sustainable healthcare systems



Steering R&D to public health needs

Ensuring the evidence base for innovation through strengthened HTA

Strengthening national P&R mechanisms in the interests of patients, payers & society

Increasing transparency around innovative pharmaceuticals

Supporting innovation in the context of sustainable healthcare systems

**Promoting
generics &
biosimilars**

**Controlling
anti-
competitive
behavior:
national & EU
level**

**Ensuring
supply of
medicines of
proven value
to patients and
health systems**

Thank you for your attention!



ESIP aisbl

Maison Européenne de la Protection Sociale

Rue d'Arlon 50 • 1000 Bruxelles • ☎ +32 2 282 05 60 • 🖨 +32 2 282 05 98

✉ esip@esip.eu • 🌐 www.esip.eu • 🐦 @ESIP_EU • VAT: BE 0808.072.950